Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain

Journal of Chemical Neuroanatomy

Volumn 40, Issue 4, 2010, Pages 272-280

  Dalton, Victoria S ^a,b   Zavitsanou, Katerina ^a,b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Autoradiography; Caudate putamen; Dopamine; Endocannabinoid; HU210; Nucleus accumbens

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DEXANABINOL; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; GROUPS BY AGE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; PERINATAL PERIOD; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR DENSITY; SUBSTANTIA NIGRA;

AGING; ANIMALS; ARABIDOPSIS PROTEINS; BRAIN; BRAIN CHEMISTRY; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TETRAHYDROCANNABINOL; TRANSCRIPTION FACTORS;

EID: 78449275726     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2010.07.005     Document Type: Article

References (70)

1. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci. Biobehav. Rev. 2003, 27:3-18.
2. Andersen S.L., Rutstein M., Benzo J.M., Hostetter J.C., Teicher M.H. Sex differences in dopamine receptor overproduction and elimination. Neuroreport 1997, 8:1495-1498.
3. Badanich K.A., Adler K.J., Kirstein C.L. Adolescents differ from adults in cocaine conditioned place preference and cocaine-induced dopamine in the nucleus accumbens septi. Eur. J. Pharmacol. 2006, 550:95-106.
4. Bossong M.G., van Berckel B.N.M., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., van Gerven J.M., Ramsey N.F., Lammertsma A.A., Kahn R.S. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
5. Breivogel C.S., Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 1998, 5:417-431.
6. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., Sim-Selley L.J. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem. 1999, 73:2447-2459.
7. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
8. Cheer J.F., Wassum K.M., Heien M.L.A.V., Phillips P.E.M., Wightman R.M. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J. Neurosci. 2004, 24:4393-4400.
9. Creese I., Sibley D.R. Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol. 1981, 21:357-391.
10. Cropley V.L., Fujita M., Innis R.B., Nathan P.J. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol. Psychiatry 2006, 59:898-907.
11. Dalton V.S., Wang H., Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem. Res. 2009, 34:1343-1353.
12. Dalton, V.S., Zavitsanou, K., 2010. Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. Synapse, doi:10.1002/syn.20801.
13. Dawson T.M., Gehlert D.R., McCabe R.T., Barnett A., Wamsley J.K. D-1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J. Neurosci. 1986, 6:2352-2365.
14. Dean B., Karl T., Pavey G., Boer S., Duffy L., Scarr E. Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr. Res. 2008, 99:341-349.
15. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., Gigerenzer G., Hoehe M.R. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl.) 1999, 142:295-301.
16. Fadda P., Scherma M., Spano M.S., Salis P., Melis V., Fattore L., Fratta W. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006, 17:1629-1632.
17. Ferrari F., Ottani A., Giuliani D. Influence of the cannabinoid agonist HU 210 on cocaine- and CQP 201-403-induced behavioural effects in rat. Life Sci. 1999, 65:823-831.
18. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997, 8:649-652.
19. Frey, K.A., Albin, R.L., 2001. Receptor binding techniques. Curr. Protoc. Neurosci., Chapter 1, Unit 1.4.
20. Gardner E.L., Vorel S.R. Cannabinoid transmission and reward-related events. Neurobiol. Dis. 1998, 5:502-533.
21. Gessa G.L., Melis M., Muntoni A.L., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 1998, 341:39-44.
22. Gorriti M.A., Rodríguez de Fonseca F., Navarro M., Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur. J. Pharmacol. 1999, 365:133-142.
23. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Porrino L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 47(Suppl. 1):345-358.
24. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 2007, 56:27-78.
25. Lamarque S., Taghzouti K., Simon H. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001, 41:118-129.
26. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
27. Lohse M.J. Molecular mechanisms of membrane receptor desensitization. Biochim. Biophys. Acta 1993, 1179:171-188.
28. MacRae P.G., Spirduso W.W., Wilcox R.E. Reaction time and nigrostriatal dopamine function: the effects of age and practice. Brain Res. 1988, 451:139-146.
29. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutiérrez S.O., van der Stelt M., López-Rodríguez M.L., Casanova E., Schütz G., Zieglgänsberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
30. Medina K.L., Hanson K.L., Schweinsburg A.D., Cohen-Zion M., Nagel B.J., Tapert S.F. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J. Int. Neuropsychol. Soc. 2007, 13:807-820.
31. Minuzzi L., Olsen A.K., Bender D., Arnfred S., Grant R., Danielsen E.H., Cumming P. Quantitative autoradiography of ligands for dopamine receptors and transporters in brain of Gottingen minipig: comparison with results in vivo. Synapse 2006, 59:211-219.
32. Monory K., Massa F., Egertová M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.-A., During M., Klugmann M., Wölfel B., Dodt H.-U., Zieglgänsberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
33. Moreno M., Lopez-Moreno J.A., Rodríguez de Fonseca F., Navarro M. Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats. Behav. Pharmacol. 2005, 16:441-446.
34. Muschamp J.W., Siviy S.M. Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats. Pharmacol. Biochem. Behav. 2002, 73:835-842.
35. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
36. Ong W.Y., Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 1999, 92:1177-1191.
37. O'Shea M., McGregor I.S., Mallet P.E. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J. Psychopharmacol. 2006, 20:611-621.
38. O'Shea M., Singh M.E., McGregor I.S., Mallet P.E. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J. Psychopharmacol. 2004, 18:502-508.
39. Parolaro D., Viganò D., Rubino T. Endocannabinoids and drug dependence. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:643-655.
40. Pattij T., Wiskerke J., Schoffelmeer A.N.M. Cannabinoid modulation of executive functions. Eur. J. Pharmacol. 2008, 585:458-463.
41. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, Sydney, Australia. 4th ed.
42. Polissidis A., Chouliara O., Galanopoulos A., Marselos M., Papadopoulou-Daifoti Z., Antoniou K. Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. Life Sci. 2009, 85:248-254.
43. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., Thompson M.R., Dawson B., Mallet P.E., Kashem M.A., Matsuda-Matsumoto H., Iwazaki T., McGregor I.S. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008, 33:1113-1126.
44. Radja F., el Mansari M., Soghomonian J.-J., Dewar K.M., Ferron A., Reader T.A., Descarries L. Changes of D1 and D2 receptors in adult rat neostriatum after neonatal dopamine denervation: quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience 1993, 57:635-648.
45. Realini N., Rubino T., Parolaro D. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol. Res. 2009, 60:132-138.
46. Rodríguez de Fonseca F., Del Arco I., Martín-Calderón J.L., Gorriti M.A., Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol. Dis. 1998, 5:483-501.
47. Rodríguez de Fonseca F., Gorriti M.A., Bilbao A., Escuredo L., García-Segura L.M., Piomelli D., Navarro M. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox. Res. 2001, 3:23-35.
48. Romero J., Berrendero F., Manzanares J., Perez A., Corchero J., Fuentes J.A., Fernández-Ruiz J.J., Ramos J.A. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 1998, 30:298-308.
49. Romero J., Lastres-Becker I., de Miguel R., Berrendero F., Ramos J.A., Fernández-Ruiz J. The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. Pharmacol. Ther. 2002, 95:137-152.
50. Rubino T., Vigano D., Realini N., Guidali C., Braida D., Capurro V., Castiglioni C., Cherubino F., Romualdi P., Candeletti S., Sala M., Parolaro D. Chronic delta(9)-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 2008, 33:2760-2771.
51. Sakurai-Yamashita Y., Kataoka Y., Fujiwara M., Mine K., Ueki S. Delta 9-tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol. Biochem. Behav. 1989, 33:397-400.
52. Schneider M., Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003, 28:1760-1769.
53. Schneider M., Schömig E., Leweke F.M. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict. Biol. 2008, 13:345-357.
54. Schramm-Sapyta N.L., Cha Y.M., Chaudhry S., Wilson W.A., Swartzwelder H.S., Kuhn C.M. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl.) 2007, 191:867-877.
55. Sim-Selley L.J., Martin B.R. Effect of chronic administration of R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-b enzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J. Pharmacol. Exp. Ther. 2002, 303:36-44.
56. Singh M.E., McGregor I.S., Mallet P.E. Repeated exposure to Delta(9)-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. Neuropharmacology 2005, 49:1189-1200.
57. Souilhac J., Poncelet M., Rinaldi-Carmona M., Le Fur G., Soubrié P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 1995, 51:3-7.
58. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
59. Tarazi F.I., Baldessarini R.J. Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain. Int. J. Dev. Neurosci. 2000, 18:29-37.
60. Teicher M.H., Andersen S.L., Hostetter J.C. Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Brain Res. Dev. Brain Res. 1995, 89:167-172.
61. Thompson B.L., Stanwood G.D. Pleiotropic effects of neurotransmission during development: modulators of modularity. J. Autism Dev. Disord. 2009, 39:260-268.
62. van der Stelt M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 2003, 480:133-150.
63. Verdurand M., Dalton V.S., Zavitsanou K. GABA(A) receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain Res. 2010, 10.1016/j.brainres.2010.06.032.
64. Viggiano D., Ruocco L.A., Sadile A.G. Dopamine phenotype and behaviour in animal models: in relation to attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 2003, 27:623-637.
65. Voruganti L.N., Slomka P., Zabel P., Mattar A., Awad A.G. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001, 107:173-177.
66. Walker Q.D., Kuhn C.M. Cocaine increases stimulated dopamine release more in periadolescent than adult rats. Neurotoxicol. Teratol. 2008, 30:412-418.
67. Weickert C.S., Webster M.J., Gondipalli P., Rothmond D., Fatula R.J., Herman M.M., Kleinman J.E., Akil M. Postnatal alterations in dopaminergic markers in the human prefrontal cortex. Neuroscience 2007, 144:1109-1119.
68. Wiley J.L., O'Connell M., Tokarz M., Wright M.E.M.J. Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. J. Pharmacol. Exp. Ther. 2007, 320:1097-1105.
69. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
70. Zavitsanou K., Wang H., Dalton V.S., Nguyen V. Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. Neuroscience 2010, 169:315-324.